NCT07575295

Brief Summary

Peroral Endoscopic Myotomy (POEM) has become an established, minimally invasive therapy for achalasia and esophageal motility disorders. Submucosal tunnelling is a critical phase of POEM and requires meticulous haemostasis to avoid bleeding, loss of orientation, reduced visibility, and prolonged procedural time. The current standard method of vessel coagulation during POEM involves conventional coagulation under CO₂ insufflation using the hybrid knife (HK). However, this approach can require additional hemostatic devices-most commonly coagulation forceps-particularly when dealing with large-calibre vessels or resistant bleeding. A novel technique-underwater preventive coagulation-leverages water as a conductive medium. Preliminary evidence suggests that:

  • electrosurgical current in water is focalized at the interface of the vessel,
  • allowing a soft sealing of the vessel wall,
  • reducing the risk of vessel rupture or unintended deep thermal injury,
  • and potentially eliminating the need to convert to coagulation forceps. Pilot data from our center demonstrate that underwater prophylactic sealing of large vessels during POEM is feasible, safe, and associated with markedly reduced need for rescue coagulation forceps. The technique is already used in practice but lacks systematic evidence from prospective randomized trials. This study is designed to provide high-quality evidence on whether underwater vessel coagulation improves haemostatic efficiency, reduces intra-procedural bleeding, and minimizes device changes during POEM. All POEM procedures will be performed under general anesthesia in the supine position using Fujifilm high-definition gastroscopes with a 2.8 mm channel and transparent distal cap. Steps (Both Arms)
  • Identify the esophagogastric junction (EGJ).
  • Inject saline + methylene blue submucosally.
  • Create a 2 cm mucosal incision at 5-6 o'clock position, 10 cm above EGJ.
  • Enter the submucosal space.
  • Perform submucosal tunnelling down to EGJ and 2-3 cm into cardia.
  • Perform vessel haemostasis according to group allocation:
  • Underwater coagulation (intervention)
  • CO₂-based conventional coagulation (control)
  • Perform circular myotomy (with occasional full-thickness myotomy when indicated).
  • Close the mucosal entry using hemostatic clips.
  • Record procedure time, instrument exchanges, bleeding events, and forceps usage.
  • Hybrid Knife (Erbe Elektromedizin GmbH)
  • VIO 3 generator + ERBEJet 2 water-jet system
  • Methylene-blue tinted saline
  • Electrosurgical settings: ENDO CUT Q 2-3-3 for mucosal incision and myotomy

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
20mo left

Started Feb 2026

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress14%
Feb 2026Dec 2027

Study Start

First participant enrolled

February 1, 2026

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

May 4, 2026

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 8, 2026

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 10, 2027

Expected
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2027

Last Updated

May 8, 2026

Status Verified

May 1, 2026

Enrollment Period

1.3 years

First QC Date

May 4, 2026

Last Update Submit

May 4, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

    1. Underwater preventive vessel coagulation, and 2. Conventional vessel coagulation under CO₂ insufflation.

    60 minutes

Secondary Outcomes (9)

  • To compare composite forceps use (rescue + prophylactic) between groups.

    60 minutes

  • To evaluate the frequency of prophylactic-only forceps use.

    60 minutes

  • To compare total number of forceps applications per procedure.

    60 minutes

  • To determine differences in intra-procedural bleeding episodes

    60 minutes

  • To compare procedural efficiency (procedure time, number of instrument exchanges

    60 minutes

  • +4 more secondary outcomes

Study Arms (2)

Under Water Coagulation

Intervention Arm: Underwater Coagulation * Vessel coagulation performed entirely underwater using the Hybrid Knife. * SWIFT COAG: E3 (89 W) for POEM. * Physiological saline instilled to completely displace air around the target vessel.

Other: Under Water Preventive Coagulation

Conventional Coagulation

Control Arm: Conventional Coagulation (CO₂ Setting) * Standard vessel isolation and coagulation under CO₂ insufflation. * SWIFT COAG: E3 (89 W) for POEM.

Interventions

Leverages water as a conductive medium. Preliminary evidence suggests that: 1. electrosurgical current in water is focalized at the interface of the vessel, 2. allowing a soft sealing of the vessel wall, 3. reducing the risk of vessel rupture or unintended deep thermal injury, 4. and potentially eliminating the need to convert to coagulation forceps.

Under Water Coagulation

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

120 (60 in each arm)

You may qualify if:

  • Age ≥ 18 years
  • Diagnosis of achalasia or esophageal motility disorder planned for POEM
  • Ability to provide informed consent

You may not qualify if:

  • Anticoagulant or antithrombotic therapy not safely stoppable
  • Known coagulopathy or platelet disorder
  • Esophageal/gastric varices
  • Previous POEM or Heller's myotomy
  • Prior treatment for same condition
  • Inability or refusal to consent
  • Visualized vessels smaller than the HK inner diameter (1.2 mm)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Asian Institute of Gastroenterology Hospital

Hyderabad, Telangana, 500082, India

RECRUITING

Study Officials

  • Mohan Dr Ramchandani, MD DM

    Asian Institute of Gastroenterology

    STUDY DIRECTOR

Central Study Contacts

Rajesh Goud Mr Maragoni, M.Pharm

CONTACT

Zaheer Nabi Dr Mohammed, MD DNB

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

May 4, 2026

First Posted

May 8, 2026

Study Start

February 1, 2026

Primary Completion (Estimated)

May 10, 2027

Study Completion (Estimated)

December 30, 2027

Last Updated

May 8, 2026

Record last verified: 2026-05

Locations